SCHEMBL13945697

SCHEMBL13945697

CC(C)(C)Oc1ccc(Oc2ccc(Cl)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.52
MAOB P27338 1/20 0.52
PPARA Q07869 6/20 0.52
CYP1A2 P05177 5/20 0.52
CYP3A4 P08684 4/20 0.52
CYP2C19 P33261 4/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
CYP2D6 P10635 3/20 0.52
MAPT P10636 3/20 0.52
PPARG P37231 3/20 0.44
ABCB11 O95342 2/20 0.44
TSHR P16473 2/20 0.44
HTR2A P28223 2/20 0.44
PMP22 Q01453 2/20 0.44
FABP2 P12104 1/20 0.44
SLC22A12 Q96S37 1/20 0.44
CYP2C9 P11712 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL196705 0.93 PPARA (0.57) MAOAMAOBPPARACYP1A2CYP3A4
SCHEMBL4820655 0.91 PPARA (0.55) MAOAMAOBPPARACYP1A2CYP3A4
SCHEMBL18866585 0.88 MAPT (0.44) CYP3A4MEN1KMT2AMAPTPPARG
SCHEMBL19339945 0.88 MAPT (0.44) CYP3A4MEN1KMT2AMAPTPPARG
SCHEMBL13019816 0.85 ALDH1A1 (0.46) MAOAMAOBPPARACYP1A2CYP3A4
SCHEMBL19339946 0.81 MAPT (0.40) CYP3A4MEN1KMT2AMAPTPPARG
SCHEMBL13945696 0.81 PPARA (0.47) PPARACYP1A2CYP3A4CYP2C19MEN1
SCHEMBL9242729 0.80 MAOA (0.74) MAOAMAOBCYP1A2CYP3A4CYP2C19
SCHEMBL26746 0.80 SLC6A2 (0.44) PPARACYP1A2CYP3A4CYP2C19MEN1
SCHEMBL457634 0.80 MAOA (0.74) MAOAMAOBCYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 US disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 US disclosed
EP-3760633-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-01-06 EP disclosed
US-20090012091-A1 Oximide derivatives and their therapeutical application KINAGEN, INC. (US) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012091-A1 Oximide derivatives and their therapeutical application CYP11B2, NOS2, HMOX2 MAOA 52/4885MAOB 35/4885PPARA 528/4885
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 MAOA 1220/4885MAOB 975/4885PPARA 2919/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 MAOA 1220/4885MAOB 975/4885PPARA 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.